Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05451849
PHASE1/PHASE2

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

Sponsor: TCR2 Therapeutics

View on ClinicalTrials.gov

Summary

TC-510 is a novel cell therapy that consists of autologous genetically engineered T cells expressing two synthetic constructs: first, a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex and second, a PD-1:CD28 switch receptor, which is expressed on the surface of the T cell, independently from the TCR. The PD-1:CD28 switch receptor comprises the PD-1 extracellular domain fused to the CD28 intracellular domain via a transmembrane domain. Thus, the switch is designed to produce a costimulatory signal upon engagement with PD-L1 on cancer cells.

Official title: A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

6

Start Date

2022-06-21

Completion Date

2028-10-30

Last Updated

2025-08-27

Healthy Volunteers

No

Interventions

BIOLOGICAL

TC-510

TC-510

DRUG

Fludarabine

Fludarabine

DRUG

Cyclophosphamide

Cyclophosphamide

Locations (7)

University of California, San Francisco

San Francisco, California, United States

University of Miami

Miami, Florida, United States

National Cancer Institute

Bethesda, Maryland, United States

University of Minnesota, Masonic Cancer Center

Minneapolis, Minnesota, United States

Montefiore Einstein Cancer Center

The Bronx, New York, United States

University of Oklahoma

Oklahoma City, Oklahoma, United States

SCRI Oncology Partners

Nashville, Tennessee, United States